Walgreens Boots Alliance — Investor Day (October 2021)
113 slides from Walgreens Boots Alliance's investor day presentation, Oct 14, 2021
Slide 1: Reimagining Healthcare for the next era
Exhibit 99.2 Walgreens Boots Alliance ~" Reimagining Healthcare for the next era
Slide 2: Safe Harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements
Safe Harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical including are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, witho
Slide 3: Opening Remarks
Opening Remarks Roz Brewer Chief Executive Officer WBA
Slide 4: 2021 Investor Day agenda
Walgreens Boots Alliance – 2021 Investor Day Opening Remarks Roz Brewer Our Purpose and Strategy John Standley Priorities Roz Brewer James Kehoe 4Q and Growth Model James Kehoe Closing Remarks Roz Brewer Q&A 4 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 5: Reimagining Healthcare for the next era
Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian
Slide 6: Six months since joining: outside-in view
no preconceived notions upon joining The past brought outside-in view 6 MONTHS of our assets have been a tremendous strengths… tremendous …great momentum and community relevance experience …but unclear strategy and disjointed culture © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 6
Slide 7: Strong foundation of assets to build on
Strong foundation of assets to build on Presence in healthcare more relevant than ever Tremendous momentum and future potential © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 7
Slide 8: Validated the role of pharmacy in local communities
Validated the role of pharmacy in local communities Completed Administered Completed more than more than more than 40 million 16 million 23 million COVID-19 COVID-19 tests same day orders vaccines to to date to date 8 © 2021 Walgreens Boots Alliance, Inc. All rights reserved. date
Slide 9: Spent $500 million on vaccination and testing capabilities
Spent $500 million to build and sustain capabilities and capacity to deliver the vaccination and testing programs 9 © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian nce, ce, I In nc. c. A All r ll rig igh ht ts s r re es se er rv ve ed d. .
Slide 10: Reimagining Healthcare for the next era
Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian
Slide 11: 4Q21 U.S. retail highlights
4Q21 U.S.: Created 6%+ retail differentiated comps omni-channel Personalization experiences 100%+ increase in digital sales to drive Engine digital and 85M+ physical traffic myWalgreens members 11 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 12: Strengthened right to win within healthcare ecosystem
Strengthened right to win within healthcare ecosystem Many assets to leverage… …and momentum as we more forward Reach in local communities (~9,000 U.S. locations) COVID-19 and underlying business Frequent touchpoints Partnerships and investments in payors with chronic customers and providers that wi
Slide 13: Developed strong customer relationships and understanding
Developed strong customer relationships and understanding Support Seekers Efficiency Enthusiasts 5+ Chronic No Chronic Conditions Conditions Wellness Watchers Concerned Caregivers 1-4 Chronic Caring for Themselves Conditions and a Loved One 13 © 2021 Walgreens Boots Alliance, Inc. All rights reserve
Slide 14: 2022 will be a year of cultivating, sharpening, investing
2022 will be a year of… CULTIVATING SHARPENING INVESTING our strengths our execution in our future 14 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 15: Focus for today
Focus for today PURPOSE Our Strategic Ambitions VISION Long-term Growth FY21 Earnings / FY22 Guidance VALUES 15 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 16: Integrated healthcare, pharmacy and retail strategy key takeaways
We have an integrated healthcare, pharmacy, and retail strategy, enabling sustainable, profitable growth We are well on our way to our new healthcare vision and ambition Key We are putting the right capabilities, assets and takeaways operating model in place from today We are committed to enhanced c
Slide 17: Our Purpose, Vision and Values
Our Purpose More joyful lives OUR Why we exist— our enduring North Star. WHY through better health. Our Vision To be the leading partner in reimagining OUR Our tangible, company-wide aspiration WHAT for the near-term. local healthcare and wellbeing for all. Our Values OUR Our shared beliefs and prin
Slide 18: Our Vision
OUR OUR Our Vision WHAT 1 WHAT Working alongside, and in service of, customers and providers 2 Looking beyond the status quo 1 to create unexpected solutions To be the leading partner 3 Serving the specific needs of each neighborhood 2 3 4 in reimagining local Healthcare: Supplying an entry point to
Slide 19: Our Strategy: Advantaged growth in community healthcare
OUR STRATEGY: Advantaged growth in community healthcare, while transforming our core Transform and align the core OUR VISION: To be the Build our next growth engine with consumer-centric healthcare leading partner solutions in reimagining local healthcare and Focus the portfolio; optimize capital we
Slide 20: Transform and Align the Core
Building the pharmacy of the Transform and Align the Core future to support and enable our healthcare strategy Transform and align the core Reimagining retail through expanded health and wellness offerings and mass Build our next growth engine personalization with consumer-centric healthcare solutio
Slide 21: Build Our Next Growth Engine
Build Our Next Growth Engine Accelerating the path to become a leading provider of local Transform and align the core clinical care services Build our next growth engine Leveraging consumer centric with consumer-centric healthcare technology and our pharmacy solutions network to deliver and enable o
Slide 22: Focus the Portfolio; Optimize Capital Allocation
Focus the Portfolio; Optimize Capital Allocation Transform and align the core Build our next growth engine Refocusing the portfolio and with consumer-centric healthcare solutions equity investments to prioritize core assets and healthcare Focus the portfolio; ambitions optimize capital allocation Ma
Slide 23: Build High-performance Culture and A Winning Team
Build High-performance Culture and A Winning Team Transform and align the core Build our next growth engine with consumer-centric healthcare solutions Focus the portfolio; optimize capital allocation Redefining our culture to drive the transformation Build a high-performance culture and a winning te
Slide 24: Transform and Align the Core
Transform and Align the Core Accelerating our core business John Standley President Walgreens
Slide 25: Empowering chronic customers on their wellness journey
Empowering chronic customers on their wellness journey Integrated, pharmacy-led, Expanded healthcare omni-channel retail health and services wellbeing destination (including clinical services, U.S. market diagnostics) 6 in 10 90% Adults have of U.S. a chronic healthcare condition spend ~$1T ~$1T TAM
Slide 26: Building the pharmacy of the future
Building the pharmacy of the future to support and enable our healthcare strategy Be the 1 Low-Cost Provider Reinvent Micro Fulfillment 2 Omni-channel Experience Pharmacy Digital Clinical of the Engagement Outcomes Future Store Role Refresh Expand Accelerate 4 3 Care Model Growth 26 © 2021 Walgreens
Slide 27: Delivering world-class pharmacy operations
Delivering world-class pharmacy operations Implementing automated central micro fulfillment capability • Freeing capacity to enable value-add healthcare activities • Reduced working capital • Improved cost-to-fill • National coverage by 2024 Expanded centralized services freeing up additional pharma
Slide 28: Reimagining Healthcare for the next era
Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian
Slide 29: Expanding health system collaboration and specialty capabilities
Expanding health system collaboration and comprehensive specialty capabilities 70 Health • 26% of health systems systems 175 Walgreens own specialty pharmacy pharmacies on- compared to 9% 87 Health in 2015 site at health systems systems • 75% of all specialty LDD prescriptions originate Access from
Slide 30: Growing beyond core pharmacy dispensing and expanding healthcare services
Growing beyond core pharmacy dispensing and expanding healthcare services Longer-term: Fundamental Short term: additional shift over vaccination and services through last 18 months testing hub healthcare strategy 30 © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian nce, ce, I In
Slide 31: Expanding robust vaccination and diagnostics offering
Expanding robust • Vaccinations • Flu, Pneumonia, Shingles, HPV, vaccination and TDAP, COVID-19 diagnostics offering • Diagnostic Testing • COVID-19 • Influenza A/B >40M COVID-19 vaccines administered • Chronic Care Management • Statins • HbA1c >16M COVID-19 • BMI, BP, Colon screening tests provided
Slide 32: Building clinical pharmacy and healthcare services
Building clinical pharmacy and healthcare services Pay for Performance ~$730B of total health spend is Disease Management attributed to modifiable risk and Care Gap Closures factors concentrated in several chronic conditions Collaborative Care Upwards of $290B in avoidable Practices healthcare costs
Slide 33: Reimagining retail through health and wellness solutions
Reimagining retail Be the first choice for health and through health and wellness solutions wellness leadership • Fueled by integrated health, pharmacy and accelerated by mass retail personalization and digitalization at personalization every step in the journey • Empowering chronic customers in the
Slide 34: Integrating health, pharmacy and retail personalization
Integrating health, pharmacy and retail personalization across the customer journey Pharmacy, health Personalized and wellness rewards wellness journeys Omni- Owned channel brand Walgreens Advertising Group Financial Services © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 34
Slide 35: Reimagining Healthcare for the next era
Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian
Slide 36: Growing new alternative profit businesses
Growing new alternative profit businesses Pharmacy, health Personalized and wellness rewards wellness journeys Omni- Owned channel brand Walgreens Financial Advertising Group services © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 36
Slide 37: Accelerating our brands and digital offerings
Accelerating our brands and digital offerings Range of products and services to meet needs Owned Brand $4.7B owned brand in FY22 Innovation 125+ new retail health products in FY22 Grow penetration to 22% by FY24 Integrated pharmacy and omni-channel experience Digital Tailored wellness journey by Off
Slide 38: Accelerating our omni-channel evolution
Accelerating our omni-channel evolution 100%+ digital sales growth vs. last year in 4Q FY21 >23M same day orders Completed across curbside, drive-thru, delivery © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 38
Slide 39: Accelerating rigorous margin management program
Accelerating rigorous margin management program Data-driven category management to fund the journey and re-invest in customer value Rigorous management Enhancement of assortment and of value levers Fund Invest space allocation the in Journey Value Direct and indirect Accelerated owned cost improveme
Slide 40: Reimagining our customer experience
Reimagining our customer experience Driving store refresh Modernizing with Optimize footprint and program to enhance technology to connect real estate expenses to experience and retail with pharmacy maximize access and increase traffic and physical with digital convenience Key messages/proof points
Slide 41: Tangible goals over the next 3 years
Creating tangible $1B+ 22% $300M+ goals over Additional TCM Owned brands In alternative savings penetration profit income the next 3 years © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 41
Slide 42: Reimagining Healthcare for the next era
Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 42
Slide 43: Accelerating omni-channel transformation of Boots UK
Health and beauty website #1 in the UK Accelerating of total sales online for omni-channel Boots UK 20%+ transformation of Boots UK portfolio AOI growth over FY20 2x as business rebounds © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 43 *4Q Data; Online Participation was 20.7% in FY21 an
Slide 44: Transforming Boots UK healthcare through telehealth, testing, vaccines
ONLINE DOC / Health Hub COVID-19 Testing Vaccines (100+ services) (3M+ delivered) (100+ locations) Transforming Boots UK healthcare through telehealth, testing, and vaccines © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 44
Slide 45: Strengthening our beauty offering
40%+ of beauty products in the UK purchased at Boots Strengthening our beauty 60+ new beauty brands introduced offering in stores and online Investing to enhance in-store experience with over 100 stores completed © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 45
Slide 46: Growing our beauty brands portfolio
Growing our beauty brands portfolio in … to become a $1B the U.S., UK, and Internationally… global business by FY23 Delivering $235M sales in the U.S.; largest growth market; +$200M over 3 years $450M in UK sales; accelerating direct-to- consumer offer Expanding our reach in China; Soap & Glory in m
Slide 47: Transformational Cost Management Program
Transformational Cost Management Program James Kehoe Global Chief Financial Officer WBA
Slide 48: Transformational Cost Management Program achievements and expansion
ü Transformational Cost Management (TCM) Program achieved $2.0B+ savings goal one year ahead of schedule through strong governance and focused execution Transformational ü Expanding TCM Program and raising savings Cost Management goal to $3.3B by FY24 Program • Higher savings from existing programs
Slide 49: TCMP Success in Accelerating Savings
TCMP Success in Accelerating Savings Raising the Bar Goal Achieved - 1 Year Ahead of Schedule $2.0B+ $2.1B $1.8B+ $1.5B+ $1.3B $1.0B+ $0.3B Original Goal Target Raised Target Raised Target Raised FY19 FY20 FY21 Dec 2018 Apr 2019 Oct 2019 Jul 2020 • Launched in FY19 with FY22 target of $1.0B+ • FY19
Slide 50: Expanding TCM Program to Fund Future Growth
Expanding TCM Program to Fund Future Growth TCM Savings Projection $3.3B • Savings target raised to $3.3B $2.1B • Comprehensive funnel of new initiatives $1.3B • Implementation costs expanded to $0.3B $3.6 to $3.9B through FY24 (compared to previous range of $2.1 to $2.3B) FY19 FY20 FY21 FY24F 1 © 2
Slide 51: $3.3B savings target driven by deep funnel of cost initiatives
$3.3B savings target driven by deep funnel of cost initiatives Smart Spend Smart Org Divisional Zero Based Budgeting and Policies Global Services Expansion Centralized Rx Services Financial Services Products Smart Organization Next AllianceRx Restructure Global Leadership Model Banking Transformatio
Slide 52: Our Next Growth Engine
Our Next Growth Engine The future of WBA as a healthcare company Roz Brewer Chief Executive Officer WBA
Slide 53: The pandemic affirmed Walgreens as a trusted neighborhood health destination
The pandemic affirmed 40M+ Walgreens as a trusted COVID-19 vaccines neighborhood health administered ~80k Pharmacists destination highlighting our and pharmacy technicians ability to help our customers across 9k locations manage their health 51% of retail pharmacy customers used 16M+ health and COVI
Slide 54: Healthcare is inherently local
Healthcare is inherently local, and all communities should have equitable access to care People plus technology deliver better care Developing a Consumer-centric, omni-channel, whole person care, healthcare delivered with privacy and security by design business built upon a core set Payment models a
Slide 55: Introducing our vision
Introducing… To be the leading partner in reimagining local healthcare and wellbeing for all © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 55
Slide 56: Maximizing Walgreens diverse assets
Maximizing Walgreens Creating better outcomes for diverse assets to deliver… consumers and partners… Delightful consumer experience with omni- Consumer-centric approach, leveraging channel engagement Walgreens trusted consumer relationships Improving health outcomes and lowering Nationally scaled, l
Slide 57: Consumer Value: orchestrating the consumer journey
Consumer Value | Orchestrating the consumer journey across the care continuum Post-acute Store Pre-acute Primary Care / Digital Community Specialty Caregivers & Patients Wellness Clinic Home Omni-channel and Personalized Consumer Engagement Platform Engaging consumers | Care team enabled by technolo
Slide 58: Partner Value: improving outcomes and costs for payors and providers
Partner Value | Bringing solutions to improve outcomes and costs for our payor and provider partners Clinical Outcomes Population Health Enabling Providers Delegated Risk Management Services and New (Primary Care and on Populations Pharmacy Models Specialists) Increasing impact on health outcomes an
Slide 59: Strategic Investments in CareCentrix and VillageMD
Strategic Investments | Announcing new strategic investments in CareCentrix and VillageMD Taking majority positions in Building upon our portfolio of Post-Acute and Primary Care assets across the care continuum Health Corner Primary Care Infusion therapies Complex and home care (home and outpatient)
Slide 60: Transforming the post-acute care journey
Transforming the post-acute care journey from hospital to home Delivering better health outcomes and enhanced patient experience while lowering costs and improving outcomes Scale Outcomes Lives under management Lower readmissions 19M 15-22% Lower emergency Spend under management ~$1.4B 11% departmen
Slide 61: VillageMD primary care delivery platform
Provides WBA with a best-in-class primary care delivery platform • VillageMD is a leading Primary care is a consumer-focused gateway to the healthcare company 1.6M+ healthcare system Patients 200+ • Superior health Clinics outcomes for patients 300k+ Over $1.4T in Value-Based Lives addressable • Ser
Slide 62: Reimagining Healthcare for the next era
Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian
Slide 63: Building consumer-centric healthcare platform: Health Corner
Building and operationalizing our consumer-centric healthcare platform Health Corner DIGITAL ENGAGEMENT PHYSICAL ENGAGEMENT Empowering people to take control of their Taking the digital experience to the next level health by connecting the dots between their by offering in-person advice and expertis
Slide 64: Walgreens Health Corner – Digital channel
Introducing Walgreens Health Corner – Digital channel CONSUMER and CAREGIVER APP HEALTH MARKETPLACE Increasing engagement Curated and personalized and improving access products and services, covered by insurance Members are supported with simple nudges, Enabling clinicians to friendly reminders, and
Slide 65: Walgreens Health Corner – Physical channel
Introducing Walgreens Health Corner – Physical channel Health Corners provide a differentiated space to deliver individualized clinical and non-clinical services PHYSICAL SPACE TECH BAR HEALTH ADVISOR Access to personalized, clinical Continuing education for Keeping the member expertise from license
Slide 66: Contracting with key payors across the industry
Contracting with key payors across the industry ~60K Medicare lives ~1.8M Commercial Lives Operational access to lives Rapidly expanding access to lives Health Corners operational Health Corners planned for ~40 200+ in market California market - at scale Customer interactions Walgreens Digital Healt
Slide 67: Reimagining Healthcare for the next era
Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian
Slide 68: Measuring success of Walgreens Health
Measuring success of Walgreens Health Future Performance * Lives Partners Sites of Care Metrics 2022: 2022: Walgreens Health Corners: Consumer Experience 2M+ 5 payor/ 100+ by YE22 1,200+ in 5 years (Physical and provider 3,000 at scale Digital) 2025: 2025: VillageMD Co-located Clinics: Consumer Expe
Slide 69: Creating a differentiated consumer-centric healthcare business
Creating a differentiated physical and digital Introducing: Walgreens Health consumer-centric healthcare business ü 2 new strategic investments in care delivery ü Walgreens Digital and Physical Health Corners operationalized ü Key strategic contracts in place with 2 partners with 1.8M+ lives under c
Slide 70: Focus the Portfolio
Focus the Portfolio Connecting investments and capital to strategy James Kehoe Global Chief Financial Officer WBA
Slide 71: Refined Capital Allocation principles
Refined Capital Allocation principles, with sharper focus ü on U.S. and healthcare Refocus Portfolio transformation started: Alliance Healthcare ü the portfolio divestiture for $6.5B proceeds and equity Optimize our portfolio of equity investments investments ü • Realign positions with strategy and
Slide 72: Capital allocation priorities sharpened to align with strategy
Capital allocation priorities sharpened to align with strategy • Healthy balance of organic investments and strategic M&A Capital • Dividends increase over time allocation • Return excess cash to shareholders (investment grade rating) priorities • Optimize portfolio of equity investments • Investmen
Slide 73: Plan to unlock value from equity investments
Comprehensive plan to unlock value from equity investments; announced CareCentrix and VillageMD strategy Priorities Recent Portfolio Actions • Streamline equity investments • Alliance Healthcare divested $6.5Bn to align with growth strategy and • iA: core pharmacy operating model synergy potential •
Slide 74: Deployed $5.5B to take majority positions in care delivery assets
Deployed capital of $5.5B to take majority positions in attractive care delivery assets VillageMD CareCentrix • $5.2B investment to raise stake to 63% • ~$330M investment for a 55% initial stake; $800M enterprise value • Leading value-based primary care provider with 230 clinics in 15 markets and gr
Slide 75: Portfolio of investments with ~$21B valuation
1 Attractive portfolio of investments with ~$21B valuation; streamlining positions to maximize returns U.S. Healthcare Investments: $19.3 - $20.5B Other Investments: $1.3 - $1.5B (1) Estimated valuation based on: (A) publicly traded companies valued based on market price as of 10/4 and (B) and priva
Slide 76: Culture and Team
Culture and Team Enabling through a high-performing culture Roz Brewer Chief Executive Officer WBA
Slide 77: Clarifying our core values
OUR HOW Clarifying our core values to enable the transformation Courageous Connected Committed Curious © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 77
Slide 78: Hiring best-in-class talent
DANIELLE GRAY HOLLY MAY Chief Legal Officer, Chief Human Resources WBA Officer, WBA Prior Experience: Prior Experience: BC NC, White House Starbucks, Abercrombie Hiring ANITA ALLEMAND best-in-class Chief Transformation and Integration Officer, WBA Prior Experience: talent to Optum, CVS Health accele
Slide 79: FY21 / 4Q Earnings
FY21 / 4Q Earnings James Kehoe Global Chief Financial Officer WBA
Slide 80: FY21 and 4Q financial highlights
FY21 and 4Q financial highlights • Strong finish to the year, exceeded expectations • 4Q continuing operations adj. EPS $1.17, +28.1% above prior year in constant Fx • FY21 continuing operations adj. EPS $4.91, +13.7% above prior year in constant Fx • Includes 34.6 million doses of COVID-19 vaccines
Slide 81: FY21 and 4Q financial highlights
FY21 and 4Q financial highlights • 4Q results reflected strong execution across the board • U.S. comparable scripts +8.8%, boosted by COVID-19 vaccines +485bps; 21% share of 4Q vaccinations • U.S. retail comp sales growth +6.2%, +7.2% excl. tobacco and e-cig • UK recovery on track and regaining mark
Slide 82: Continuing adjusted EPS grew +28.1% in 4Q
Continuing adjusted EPS grew +28.1% in 4Q; +13.7% in FY21 B/(W) vs. 4Q20 B/(W) vs. FY20 Results 4Q21 FY21 $ in millions (except EPS) Reported Fx Constant Fx Reported Fx Constant Fx Sales (continuing) $34,262 + 12.8% + 11.8% $132,509 + 8.6% + 7.5% Operating income (continuing) GAAP $910 + 49.7% $2,34
Slide 83: Adjusted 4Q21 AOI growth of 22%
Adjusted 4Q21 AOI growth of 22% led by strong adjusted gross profit growth in both segments 4Q21 FY21 Results $ in millions WBA U.S. Intl WBA U.S. Intl Sales (continuing) $34,262 $28,755 $5,507 $132,509 $112,005 $20,505 % B/(W) vs. prior year + 11.8% + 6.6% + 52.6% + 7.5% + 4.0% + 34.1% Adjusted gro
Slide 84: Long-Term Growth
Long-Term Growth Reimagining Healthcare for the next era a
Slide 85: Long-term EPS growth algorithm in the low teens
Long-term EPS growth algorithm in the low teens, driven by advantaged healthcare business and moderate core growth Long Term Growth Algorithm highly influenced by pace of healthcare ü investments and capital allocation (organic vs inorganic) • 3 reporting segments in FY22: U.S., International, Walgr
Slide 86: Long-term growth – Corporate Assumptions
Long-term growth – Corporate Assumptions Tax rate trending higher (mix, higher rate U.S. income); FY22 16%, ü Rising FY23 18.5%, FY24 20%, +50bps per annum thereafter Tax Rate Implications of current legislative proposals not considered ü Limited Share Not a priority in the short-term, focus on cred
Slide 87: Long-term growth – International Segment Assumptions
Long-term growth – International Segment Assumptions AOI growth of >50% in FY22, with sales up +8-10% ü Strong AOI • Led by Boots UK strength, with AOI growing +55-60% growth over next 3 years International 3-yr AOI CAGR +25-30%: sales CAGR of +4-5% ü • Led by Boots UK 3-year AOI CAGR of >25% Sales
Slide 88: Long-term growth – U.S. Segment Assumptions
Long-term growth – U.S. Segment Assumptions Vaccinations FY21: 34.6M, FY22: ~25M ü Minimum Wage (gross impact): $(450)M over three years Headwinds ü AllianceRx (ARxWP): Sales $(8)B, AOI $(100)M in FY22 ü Retail momentum exiting FY21, ROI on omni-investments ü Tailwinds New business: Financial servic
Slide 89: Long-term growth – Walgreens Health Segment Assumptions
Long-term growth – Walgreens Health Segment Assumptions Sizeable sales potential: ü • Walgreens Health organic sales potential of at least $3.5B • M&A sales outlook (CCX, VMD, Shields): FY22 ~$3B, FY25 $9-10B Attractive margin profile, above base WBA business ü EPS impact is material to WBA, contrib
Slide 90: Long-term algorithm shows EPS growth accelerating to low teens
Long-term algorithm shows EPS growth accelerating to low teens, as healthcare segment scales up and margins build Next LT-growth 3-years algorithm (FY25+) 4.5% 2.5-3% Base Healthcare 0.5% 6.5-7.5% (1)% (1)% Tax rate Share repurchases -% 3.0-3.5% EPS growth % (constant Fx) ~4% 11-13% 90 Note: All ref
Slide 91: FY22 Guidance
FY22 Guidance Reimagining Healthcare for the next era a
Slide 92: FY22 base growth of 4% and headwinds
Base growth of 4% includes over 8%p of headwinds, primarily from vaccines (4%p) and growth investments (3%p) FY22 EPS GROWTH DRIVERS OF BASE GROWTH: +4% Base +4% Vaccines and testing (4) Healthcare Organic (3)% Higher investments (3) Healthcare M&A (1)% Minimum wage (1) ABC equity earnings 4 Interna
Slide 93: Organic healthcare investment in FY22
Organic healthcare investment of $(210)-$(230)M in FY22, reduces EPS growth by 3%p FY22 EPS GROWTH WALGREENS HEALTH ORGANIC FY22: Base +4% Healthcare Organic (3)% AOI ($ M) $ (210)-(230) Healthcare M&A (1)% EPS $ (0.18) – (0.21) Adjusted EPS: flat Note: All references to EPS or EPS growth refer to A
Slide 94: Healthcare M&A dilutive in FY22
Healthcare M&A will be ($0.05) to ($0.10) cents dilutive in FY22 FY22 EPS GROWTH HEALTHCARE M&A FY22: Base +4% Healthcare Organic (3)% Healthcare M&A (1)% Sales ($ B) $ 3.0-3.2 EPS $ (0.05) - $(0.10) Adjusted EPS: flat Note: All references to EPS or EPS growth refer to Adjusted Continuing EPS at con
Slide 95: Strong start – 1H EPS growth +15-18%
Expecting strong start – 1H EPS growth +15-18%; full year base growth tempered by investments / lapping vaccines FY22 EPS GROWTH 1H: +15-18% Base +4% Lapping weak FY21 C/C/Flu Healthcare Organic (3)% Higher vaccines 1H22 Healthcare M&A (1)% 2H: (14)-(17)% Tough prior year comps (vaccinations) Adjust
Slide 96: Long-term algorithm shows EPS growth accelerating to low teens
Long-term algorithm shows EPS growth accelerating to low teens, as healthcare segment scales up and margins build Next LT-growth 3-years algorithm (FY25+) 4.5% 2.5-3% Base Healthcare 0.5% 6.5-7.5% (1)% (1)% Tax rate Share repurchases -% 3.0-3.5% EPS growth % (constant Fx) ~4% 11-13% 96 Note: All ref
Slide 97: Closing Comments and Future Outlook
Closing Comments and Future Outlook Roz Brewer Chief Executive Officer WBA
Slide 98: Future growth driven by advantaged healthcare position
Future growth to be driven by our advantaged healthcare position Model shows accelerating EPS growth as WBA pivots deeper into ü healthcare and creates an innovative and advantaged business model EPS growth at ~4% CAGR first 3-years, held back by FY22 investments, ü lower vaccines Long-term growth m
Slide 99: Integrated healthcare, pharmacy and retail strategy summary
We have an integrated healthcare, pharmacy, and retail strategy, 1 enabling sustainable, profitable growth We are well on our way to our new healthcare vision and ambition 2 We are putting the right capabilities, assets, and operating model in 3 place We are committed to enhanced communication and t
Slide 100: Q&A
Q&A 100 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 101: Reimagining Healthcare for the next era
Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences 10 © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 1
Slide 102: Endnotes
Endnotes ◦ Unless otherwise noted, all prior year numbers have been recast for continuing operations. Refer to WBA's Current Report on Form 8-K filed on March 31, 2021. ◦ Please see appendix for reconciliations of non-GAAP financial measures and related disclosures • The company presents certain inf
Slide 103: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente
Slide 104: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent
Slide 105: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent
Slide 106: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent
Slide 107: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent
Slide 108: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBe
Slide 109: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2021 Walgreens Boots 1 United States International Corporate and Other Alliance, Inc. Sales $ 28,755 $ 5,507 $ — $ 34,262 Gro
Slide 110: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Three months ended August 31, 2020 Walgreens Boots (in millions) 1 United States International Corporate and Other Alliance, Inc. Sales $ 26,967 $ 3,403 $ — $ 30,371 Gro
Slide 111: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2021 Walgreens Boots 1 United States International Corporate and Other Alliance, Inc. Sales $ 112,005 $ 20,505 $ — $ 132,509
Slide 112: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Twelve months ended August 31, 2020 Supplemental Information (unaudited) Walgreens Boots (in millions) 1 United States International Corporate and Other Alliance, Inc. Sales $ 107,701 $ 14,281 $ — $ 121,982
Slide 113: Reconciliation of Non-GAAP financial measures: free cash flow
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended August 31, Twelve months ended August 31, 2021 2020 2021 2020 Net cash provided by operating activities (GAAP) $ 1,245 $
Walgreens Boots Alliance — Investor Day (October 2021) on 6ix